Lisa Allander
Overview
Explore the profile of Lisa Allander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allander L, Vickberg K, Fermer E, Soderhall T, Sandegren L, Lagerback P, et al.
Antimicrob Agents Chemother
. 2024 Oct;
68(11):e0076224.
PMID: 39365067
Combinations of colistin and β-lactam/β-lactamase inhibitors (BLBLIs) have shown synergy against β-lactamase-producing strains. However, data are limited and conflicting, potentially attributed to variations among the examined strains. This study investigated...
2.
Ormala-Tiznado A, Allander L, Maatallah M, Kabir M, Brisse S, Sandegren L, et al.
Microbiol Spectr
. 2024 Jan;
12(2):e0403622.
PMID: 38205958
Extensively drug-resistant (XDR) inflict a notable burden on healthcare worldwide. Of specific concern are strains producing carbapenem-hydrolyzing enzymes, as the therapeutic options for these strains are still very limited. Specific...
3.
Olsson A, Allander L, Shams A, Al-Farsi H, Lagerback P, Tangden T
Int J Antimicrob Agents
. 2023 Sep;
62(5):106967.
PMID: 37716575
Background: Combination therapy can enhance the activity of available antibiotics against multidrug-resistant Gram-negative bacteria. This study assessed the effects of polymyxin B combinations against carbapenemase-producing Klebsiella pneumoniae (K. pneumoniae). Methods:...
4.
Allander L, Vickberg K, Lagerback P, Sandegren L, Tangden T
Antibiotics (Basel)
. 2022 Nov;
11(11).
PMID: 36421290
Double-carbapenem combinations have shown synergistic potential against carbapenemase-producing but data remain inconclusive. This study evaluated the activity of double-carbapenem combinations against 51 clinical KPC-2-, OXA-48-, NDM-1, and NDM-5-producing and and...
5.
Dahdouh E, Allander L, Falgenhauer L, Iorga B, Lorenzetti S, Marcos-Alcalde I, et al.
Int J Mol Sci
. 2022 Sep;
23(17).
PMID: 36077146
The EPIC consortium brings together experts from a wide range of fields that include clinical, molecular and basic microbiology, infectious diseases, computational biology and chemistry, drug discovery and design, bioinformatics,...
6.
Rajer F, Allander L, Karlsson P, Sandegren L
Antimicrob Agents Chemother
. 2022 Jun;
66(6):e0029022.
PMID: 35652643
β-Lactam antibiotics are the first choice for the treatment of most bacterial infections. However, the increased prevalence of β-lactamases, in particular extended-spectrum β-lactamases, in pathogenic bacteria has severely limited the...
7.
Palica K, Voracova M, Skagseth S, Andersson Rasmussen A, Allander L, Hubert M, et al.
ACS Omega
. 2022 Feb;
7(5):4550-4562.
PMID: 35155946
Being the second leading cause of death and the leading cause of disability-adjusted life years worldwide, infectious diseases remain-contrary to earlier predictions-a major consideration for the public health of the...